Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from EPS Creative Health Technology Group Limited ( (HK:3860) ) is now available.
EPS Creative Health Technology Group Limited has signed a non-binding memorandum of understanding to acquire a 16.23% indirect minority interest in China Genetic Limited, which controls a majority stake in Shanghai Huaxin Biotechnology Co., Ltd., a biopharmaceutical company in mainland China. The proposed consideration of approximately HK$40 million to HK$45 million will be paid in cash, funded by internal resources and potentially future fundraising, and remains subject to due diligence, independent shareholder approval, absence of material adverse changes, and necessary regulatory consents; if completed, the stake will be recorded as an associate investment and is expected to broaden EPS Creative Health’s exposure to biopharmaceutical R&D and manufacturing, strengthening its strategic positioning and growth prospects in the wider healthcare industry.
The most recent analyst rating on (HK:3860) stock is a Buy with a HK$0.83 price target. To see the full list of analyst forecasts on EPS Creative Health Technology Group Limited stock, see the HK:3860 Stock Forecast page.
More about EPS Creative Health Technology Group Limited
EPS Creative Health Technology Group Limited operates in the healthcare sector, with core businesses in healthcare product trading, medical device leasing, and the provision of contract research organisation (CRO) services. The group focuses on expanding its presence across the broader healthcare industry through synergistic and complementary investments and operations in Greater China.
Average Trading Volume: 233,285
Technical Sentiment Signal: Buy
Current Market Cap: HK$365.5M
For a thorough assessment of 3860 stock, go to TipRanks’ Stock Analysis page.